Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema

NCT03396861•Tufts Medical Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Irvine-Gass Syndrome

Interventions

Aflibercept

Locations

United States

Locations (1)

Tufts Medical Center

Boston, Massachusetts, United States

Key Dates

Start Date

February 22, 2019

Primary Completion Date

August 18, 2019

Completion Date

January 2, 2020

Last Updated

October 15, 2024

Sponsors

Lead Sponsor

Tufts Medical Center

Collaborators

Regeneron Pharmaceuticals

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions